Medtronic Reports First Quarter Fiscal 2022 Financial Results

Go back to Medtronic Reports First Quarter Fiscal 2022 Financial Results

Medtronic, Inc. (MDT) PT Raised to $155 at Jefferies

August 25, 2021 7:30 AM EDT

Jefferies analyst Raj Denhoy raised the price target on Medtronic, Inc. (NYSE: MDT) to $155.00 (from $145.00) while maintaining a Buy rating.

The analyst commented, "MDT posted a ~$120mn/$0.10 beat on out-performance in MedSurg on elective procedure recovery, share gains in Cardio/Micra,... More

Medtronic, Inc. (MDT) PT Raised to $145 at Stifel

August 25, 2021 6:33 AM EDT

Stifel analyst Rick Wise raised the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $140.00) while maintaining a Buy rating.

The analyst commented, "Despite some signs of new COVID-related slowdowns in late-July, Medtronic did start the F2022 year with a better-than-expected overall performance. Nicely-exceeding Stifel/Consensus estimates (Sales: $7.866B/$7.871B; EPS: $1.32), Medtronic reported F1Q sales... More

Medtronic (MDT) Tops Q1 EPS by 9c, Raises EPS Guidance

August 24, 2021 6:47 AM EDT

Medtronic (NYSE: MDT) reported Q1 EPS of $1.41, $0.09 better than the analyst estimate of $1.32. Revenue for the quarter came in at $7.99 billion versus the consensus estimate of $7.85 billion.

GUIDANCE:

Medtronic sees FY2022 EPS of $5.65-$5.75, versus the consensus of... More